Oxycodone 10mg Pink K56

Descripción Del Producto

Oxycodone hydrochloride 10 mg oral tablets bearing the “K 56” imprint represent one of the most widely prescribed intermediate-strength immediate-release opioid formulations used in clinical pain management. In forensic toxicology and illicit marketplace surveillance, this specific physical presentation represents one of the most frequently targeted dosage units for clandestine replication. Because legitimate pharmaceutical demand is high, illicit manufacturing networks deploy rotary tablet presses with counterfeit “K 56” punch dies to compress inert binders, coloring agents, and illicit synthetic opioids (principally illicitly manufactured fentanyl and novel potent benzimidazole opioids/nitazenes) into counterfeit tablets that mimic the appearance of genuine diverted pharmaceuticals.

Pharmaceutical Profile & Physical Architecture

• Active Pharmaceutical Ingredient: Oxycodone hydrochloride (10 mg per tablet, equivalent to 8.96 mg of pure oxycodone freebase).

• Chemical Family: Semi-synthetic morphinan-derivative alkaloid synthesized from the natural opium alkaloid thebaine.

• Molecular Formula & Mass: $\text{C}_{18}\text{H}_{21}\text{NO}_4 \cdot \text{HCl}$ | 315.36 g/mol (freebase), 351.82 g/mol (hydrochloride salt).

• Physical Presentation (Authentic KVK-Tech Formulation):

  • Form: Small, round, biconvex film-coated or uncoated compressed oral tablet.

  • Color: Light pink to pale salmon, formulated with standardized pharmaceutical colorants (typically D&C Red #27 aluminum lake and FD&C Blue #2 aluminum lake).

  • Imprint Architecture: Debossed with the letter “K” on the obverse face; debossed with the numeral “56” on the reverse face, bisected by a functional single score line designed to facilitate half-tablet division.

  • Excipients: Microcrystalline cellulose, lactose monohydrate, stearic acid, and colloidal silicon dioxide.

Pharmacodynamics & Mechanism of Action

• Mu-Opioid Receptor ($\mu$-OR) Agonism: Oxycodone functions as a full agonist with high selectivity for the $\mu$-opioid receptor (MOR) coupled to heterotrimeric $G_i/G_o$ proteins, with lower affinity at $\kappa$-opioid (KOR) and $\delta$-opioid (DOR) receptors.

• Intracellular Signal Transduction: Receptor binding prompts dissociation of the $G_{\beta\gamma}$ y $G_{\alpha i}$ subunits, inhibiting adenylyl cyclase (reducing intracellular cyclic $\text{AMP}$ synthesis). Downstream cascades close presynaptic N-type voltage-gated calcium channels (inhibiting the exocytosis of nociceptive neurotransmitters, including Substance P, glutamate, and calcitonin gene-related peptide [CGRP]) and activate inwardly rectifying potassium channels ($\text{GIRK}$), hyperpolarizing postsynaptic neuronal membranes.

• Neuroanatomical Impact: Dampens ascending nociceptive conduction at the level of the spinal cord dorsal horn (substantia gelatinosa) while activating descending pain-modulating pathways in the periaqueductal gray ($\text{PAG}$) and rostral ventromedial medulla ($\text{RVM}$). Euphoria and high psychological abuse liability are driven by disinhibition of dopaminergic neurons in the ventral tegmental area ($\text{VTA}$) via MOR-mediated inhibition of local GABAergic interneurons.

Pharmacokinetics & Biotransformation

• Absorption & Bioavailability: Rapid systemic absorption following oral ingestion, achieving an oral bioavailability between 60% and 87% (significantly higher than oral morphine due to reduced first-pass hepatic metabolism afforded by the 3-methoxy substitution). Peak plasma concentrations ($C_{\max}$) occur within 1.0 to 1.5 hours in the fasted state.

• Distribution & Protein Binding: Approximately 38% to 45% bound to human plasma proteins (predominantly albumin). Apparent volume of distribution ($V_d$) is approximately $2.6\text{ L/kg}$, indicating extensive tissue penetration.

• Hepatic Metabolism & Cleared Pathways:

  • CYP3A4/5 Pathway (Major): Responsible for $N$-demethylation into noroxycodone, its primary circulating metabolite, which possesses weak opioid analgesic activity.

  • CYP2D6 Pathway (Minor but Potent): Responsible for $O$-demethylation into oxymorphone, a clinically potent $\mu$-opioid agonist with 10- to 14-fold higher MOR affinity than parent oxycodone. (Poor or ultra-rapid CYP2D6 metabolizer phenotypes can introduce significant variance in clinical response).

• Elimination: Displays an elimination half-life ($t_{1/2}$) of 3.2 to 4.5 hours. Excreted almost entirely via the renal route, with approximately 19% excreted as free or conjugated parent oxycodone, alongside glucuronidated metabolites.

Clandestine Counterfeiting & Illicit Toxicology

• The “Dirty 10” Phenomenon: Forensic seizures across North America increasingly document counterfeit “K 56” exhibits substituted with synthetic opioids.

• Illicit Adulterants & Potency Hazards:

  • Fentanyl & Novel Analogues: Counterfeit presses frequently contain 1 mg to 5+ mg of illicitly synthesized fentanyl base or fluorofentanyl, doses capable of inducing fatal respiratory depression in opioid-tolerant or opioid-naive individuals.

  • Nitazene Class Synthetics: Identification of high-potency synthetic 2-benzylbenzimidazole derivatives (e.g., isotonitazene, metonitazene, protonitazene), which exhibit potencies up to several dozen times greater than morphine and show reduced response to standard naloxone dosing intervals.

  • Binder Inconsistencies & Hotspots: Clandestine dry-powder blending lacks pharmaceutical-grade geometric dilution, creating severe intra-tablet and inter-tablet potency variations (“hotspots”).

Analytical Screening & Forensic Identification

• Presumptive Reagent Testing:

  • Marquis Reagent: Yields a slow, faint transition from clear to a dull violet or pale pinkish-purple (differentiating it from the rapid, deep purple-black seen with codeine or morphine).

  • Mecke Reagent: Produces an immediate transition to olive green, gradually shifting toward a dark blue-green over several minutes.

  • Froehde Reagent: Produces an initial yellow-to-olive transition, gradually settling into a dull blue or blue-gray hue.

  • Fentanyl Lateral Flow Strips (Harm Reduction / Field Casework): Essential for verifying the presence or absence of clandestine synthetic opioid contamination down to concentrations of 20 to 100 ng/mL.

• Instrumental Profiling & Chromatography:

  • Gas Chromatography-Mass Spectrometry (GC-MS, EI): Electron ionization ($70\text{ eV}$) yields characteristic diagnostic fragment ions with a dominant molecular/base ion at $m/z$ 315 ($[M]^+$), with prominent confirmatory diagnostic fragments at $m/z$ 258 ($[M – \text{C}_3\text{H}_7\text{N}]^+$), $m/z$ 230, $m/z$ 70, and $m/z$ 59.

  • LC-MS/MS & Chiral Liquid Chromatography: Used for the quantitative separation of oxycodone from its primary metabolites (noroxycodone, oxymorphone, noroxymorphone) and the simultaneous ultra-trace detection of synthetic cutting agents, veterinary sedatives (xylazine), or fentanyl analogues.

Regulatory Classification & Institutional Governance

• Controlled Substance Classification: Genuine oxycodone is classified as a Schedule II controlled substance under the United States Controlled Substances Act (high potential for abuse, severe psychological or physical dependence liability, with accepted medical indications). It is a Class A controlled drug in the United Kingdom under the Misuse of Drugs Act 1971 and cataloged under Schedule I of the UN Single Convention on Narcotic Drugs, 1961.

• Compliance Protocols: Procurement, storage, reference standard calibration, and disposal mandate active Schedule II DEA researcher registration, certified double-lock vault containment, DEA Form 222 execution, and strict chain-of-custody logging.

Información Adicional